Xilio Therapeutics (XLO) Operating Margin (2024 - 2026)
Xilio Therapeutics' (XLO) quarterly Operating Margin came in at 18.68% in Q2 2026, up 15903.0% year-over-year from N/an in Q2 2025, and up 83.26% quarter-over-quarter from 111.57% in Q1 2026.
Powered by 
Analysis
Xilio Therapeutics (XLO) Operating Margin (2024 - 2026) Analysis & Trends
Xilio Therapeutics has disclosed Operating Margin across 3 years of filings, most recently posting 18.68% for Q2 2026.
- In Q2 2026, Operating Margin rose 15903.0% year-over-year to 18.68%; the TTM figure through Jun 2026 stood at 48.94% (up 32842.0% YoY), while the FY2025 annual figure was 95.92%, up 85903.0% from the prior year.
- Operating Margin came in at 18.68% for Q2 2026 at Xilio Therapeutics, up from 111.57% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 10.12% in Q3 2025 to a low of 790.55% in Q4 2024.
- Average Operating Margin over 3 years is 327.11%, with a median of 177.71% recorded in 2025.
- Year-over-year, Operating Margin surged 70406 bps in 2025 and jumped 15903 bps in 2026.
- Over 3 years, Operating Margin stood at 790.55% in 2024, then jumped by 89 bps to 86.48% in 2025, then surged by 78 bps to 18.68% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 18.68% in Q2 2026, 111.57% in Q1 2026, and 86.48% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Xilio Therapeutics | 174.55 Mn | 38.51 Mn | - | -18.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18.68% |
| Mar 31, 2026 | -111.57% |
| Dec 31, 2025 | -86.48% |
| Sep 30, 2025 | -10.12% |
| Jun 30, 2025 | -177.71% |
| Mar 31, 2025 | -472.73% |
| Dec 31, 2024 | -790.55% |
| Sep 30, 2024 | -652.32% |
| Jun 30, 2024 | -623.84% |